Melanin concentrating hormone antagonists

Abstract

The present invention relates to compounds capable of serving as moderators of human and mammalian appetite and as such provide a means for reducing body mass and controlling obesity.

1 .- 14 . (canceled)  
     
     
         15 . A method for controlling obesity in humans and higher mammals, said method comprising the step of administering to a human or higher mammal an effective amount of one or more compounds, according to claim  1 .  
     
     
         16 . A method for controlling weight gain in humans and higher mammals, said method comprising administering to a human or higher mammal an effective amount of one or more compounds according to claim  1 .  
     
     
         17 . A method for controlling the body weight of humans and higher mammals, said method comprising administering to a human or higher mammal an effective amount of one or more compounds according to claim  1 .  
     
     
         18 . A method for controlling anxiety in humans and higher mammals, said method comprising administering to a human or higher mammal an effective amount of one or more compounds according to claim  1 .  
     
     
         19 . A method for controlling depression in humans and higher mammals, said method comprising administering to a human or higher mammal an effective amount of one or more compounds according to claim  1 .  
     
     
         20 . A method for controlling in humans one or more diseases, disease states, conditions, or syndromes relating to behavior, said diseases, disease states, conditions, or syndromes are chosen from memory impairment (including learning), cardiovascular function, inflammation, sepsis, cardiogenic and hypovolemic shock, sexual dysfunction, penile erection, muscle atrophy, nerve growth and repair, and intrauterine fetal growth, said method comprising administering to a human an effective amount of one or more compounds according to claim  1 .  
     
     
         21 . A method for controlling in humans one or more diseases, disease states, conditions, or syndromes resulting from body weight disorders, said diseases, disease states, conditions, or syndromes are chosen from insulin resistance, glucose intolerance, Type-2 diabetes mellitus, coronary artery disease, elevated blood pressure, hypertension, dyslipidaemia, endometrial cancer, cervical cancer, ovarian cancer, breast cancer, prostate cancer, gallbladder cancer, colon cancer, menstrual irregularities, hirsutism, infertility, gallbladder disease, restrictive lung disease, sleep apnea, gout, osteoarthritis, and thromboembolic disease, said method comprising administering to a human an effective amount of one or more compounds according to claim  1 .